rs11575937
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 15 ACMG points: 15P and 0B. PM1PM2PM5PP2PP5_Very_Strong
The NM_170707.4(LMNA):c.1445G>A(p.Arg482Gln) variant causes a missense change. The variant allele was found at a frequency of 0.00000248 in 1,614,080 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R482L) has been classified as Pathogenic.
Frequency
Genomes: 𝑓 0.000013 ( 0 hom., cov: 32)
Exomes 𝑓: 0.0000014 ( 0 hom. )
Consequence
LMNA
NM_170707.4 missense
NM_170707.4 missense
Scores
6
7
7
Clinical Significance
Conservation
PhyloP100: 4.19
Genes affected
LMNA (HGNC:6636): (lamin A/C) The protein encoded by this gene is part of the nuclear lamina, a two-dimensional matrix of proteins located next to the inner nuclear membrane. The lamin family of proteins make up the matrix and are highly conserved in evolution. During mitosis, the lamina matrix is reversibly disassembled as the lamin proteins are phosphorylated. Lamin proteins are thought to be involved in nuclear stability, chromatin structure and gene expression. Vertebrate lamins consist of two types, A and B. Alternative splicing results in multiple transcript variants. Mutations in this gene lead to several diseases: Emery-Dreifuss muscular dystrophy, familial partial lipodystrophy, limb girdle muscular dystrophy, dilated cardiomyopathy, Charcot-Marie-Tooth disease, and Hutchinson-Gilford progeria syndrome. [provided by RefSeq, May 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 15 ACMG points.
PM1
In a strand (size 3) in uniprot entity LMNA_HUMAN there are 7 pathogenic changes around while only 0 benign (100%) in NM_170707.4
PM2
Very rare variant in population databases, with high coverage;
PM5
Other missense variant is known to change same aminoacid residue: Variant chr1-156136985-G-T is described in Lovd as [Pathogenic].
PP2
Missense variant in gene, where missense usually causes diseases (based on misZ statistic), LMNA. . Gene score misZ 2.3673 (greater than the threshold 3.09). Trascript score misZ 3.0905 (greater than threshold 3.09). GenCC has associacion of gene with familial partial lipodystrophy, Dunnigan type, autosomal recessive Emery-Dreifuss muscular dystrophy, LMNA-related cardiocutaneous progeria syndrome, atrioventricular block, dilated cardiomyopathy 1A, Emery-Dreifuss muscular dystrophy 2, autosomal dominant, atypical Werner syndrome, restrictive dermopathy 1, autosomal semi-dominant severe lipodystrophic laminopathy, Emery-Dreifuss muscular dystrophy 3, autosomal recessive, dilated cardiomyopathy, Charcot-Marie-Tooth disease type 2B1, dilated cardiomyopathy-hypergonadotropic hypogonadism syndrome, arrhythmogenic right ventricular cardiomyopathy, familial isolated dilated cardiomyopathy, mandibuloacral dysplasia with type A lipodystrophy, autosomal dominant Emery-Dreifuss muscular dystrophy, heart-hand syndrome, Slovenian type, congenital muscular dystrophy due to LMNA mutation, lethal restrictive dermopathy, Hutchinson-Gilford progeria syndrome.
PP5
Variant 1-156136985-G-A is Pathogenic according to our data. Variant chr1-156136985-G-A is described in ClinVar as [Pathogenic]. Clinvar id is 14486.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr1-156136985-G-A is described in Lovd as [Pathogenic]. Variant chr1-156136985-G-A is described in Lovd as [Likely_pathogenic].
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| LMNA | NM_170707.4 | c.1445G>A | p.Arg482Gln | missense_variant | 8/12 | ENST00000368300.9 | NP_733821.1 | |
| LMNA | NM_005572.4 | c.1445G>A | p.Arg482Gln | missense_variant | 8/10 | ENST00000677389.1 | NP_005563.1 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| LMNA | ENST00000368300.9 | c.1445G>A | p.Arg482Gln | missense_variant | 8/12 | 1 | NM_170707.4 | ENSP00000357283 | P1 | |
| LMNA | ENST00000677389.1 | c.1445G>A | p.Arg482Gln | missense_variant | 8/10 | NM_005572.4 | ENSP00000503633 |
Frequencies
GnomAD3 genomes 0.0000131 AC: 2AN: 152204Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
2
AN:
152204
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.00000137 AC: 2AN: 1461876Hom.: 0 Cov.: 32 AF XY: 0.00000138 AC XY: 1AN XY: 727234
GnomAD4 exome
AF:
AC:
2
AN:
1461876
Hom.:
Cov.:
32
AF XY:
AC XY:
1
AN XY:
727234
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome 0.0000131 AC: 2AN: 152204Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74358
GnomAD4 genome
AF:
AC:
2
AN:
152204
Hom.:
Cov.:
32
AF XY:
AC XY:
0
AN XY:
74358
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
1
ExAC
AF:
AC:
1
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:17Uncertain:1Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Familial partial lipodystrophy, Dunnigan type Pathogenic:5
| Pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University of Leipzig Medical Center | May 30, 2022 | Criteria applied: PS3,PS4,PM5_STR,PM1,PM2_SUP,PP3 - |
| Pathogenic, no assertion criteria provided | literature only | OMIM | Mar 01, 2013 | - - |
| Pathogenic, no assertion criteria provided | research | CSER _CC_NCGL, University of Washington | Jun 01, 2014 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Neuberg Centre For Genomic Medicine, NCGM | - | The missense variant p.R482Q in LMNA (NM_170707.4) has been previously reported in individuals with familial partial lipodystrophy type 2 and is a mutational hot spot for the same(Jacob KN et al).Mice models are consistent with a phenotype of FPL D (Wojtanik 2009).It has been submitted to ClinVar as Pathogenic .The missense variant c.1445G>A (p.R482Q) in LMNA (NM_170707.4) is not observed in the large population cohorts of the gnomAD and 1000 Genomes datasets (Exome Aggregation Consortium et al., 2016; 1000 Genomes Consortium et al., 2015)The p.R482Q variant is novel (not in any individuals) in gnomAD Exomes and is novel (not in any individuals) in 1000 Genomes. The p.R482Q missense variant is predicted to be damaging by both SIFT and PolyPhen2. The arginine residue at codon 482 of LMNA is conserved in all mammalian species. The nucleotide c.1445 in LMNA is predicted conserved by GERP++ and PhyloP across 100 vertebrates. For these reasons, this variant has been classified as Pathogenic. - |
| Pathogenic, no assertion criteria provided | clinical testing | Genetic Services Laboratory, University of Chicago | Nov 12, 2020 | DNA sequence analysis of the LMNA gene demonstrated a sequence change, c.1445G>A, in exon 8 that results in an amino acid change, p.Arg482Gln. This sequence change has been described in the EXAC database with a low population frequency of 0.001% (dbSNP rs11575937). The p.Arg482Gln variant in LMNA has been reported in multiple families with Dunnigan-type familial partial lipodystrophy (FPLD) and co-segregated with affected individuals (PMIDs: 10587585, 10999791, 19418082, 19859838, 20130076, 20625965, 26662654). Transgenic mice expressing the p.Arg482Gln variant showed increase blood insulin levels, reduced insulin sensitivity, and impaired adipocyte differentiation, consistent with the clinical phenotypes observed in patients (PMID: 19201734). Furthermore, other missense changes at this same position (p.Arg482Trp and p.Arg482Leu) have also been implicated in familial partial lipodystrophy (PMIDs: 10655060, 10739751). - |
not provided Pathogenic:4Other:1
| Pathogenic, criteria provided, single submitter | clinical testing | Center for Pediatric Genomic Medicine, Children's Mercy Hospital and Clinics | Jan 04, 2017 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Aug 11, 2017 | The LMNA c.1445G>A, p.Arg482Gln variant (rs11575937) has been reported in multiple families with familial partial lipodystrophy (Dunnigan-type) (Cao 2000, Drac 2010, Gamberini 2008, Hegele 2000, Hegele 2000b, Imachi 2009, Ludtke 2005, Shackleton 2000, Speckman 2000, Vigouroux 2000), and co-segregated with affected individuals (Cao 2000, Hegele 2000, Speckman 2000). Other missense variants at this position (p.Arg482Trp and p.Arg482Leu) have also been implicated in familial partial lipodystrophy (Hegele 2000b, Shackleton 2000, Speckman 2000, Vigouroux 2000). The variant protein appears to have no significant impact on the structural integrity of the nucleus, but appears to decrease Lamin B2 expression (Zwerger 2013). Transgenic mice expressing the human variant protein shows increase blood insulin levels, reduced insulin sensitivity, and impaired adipocyte differentiation, consistent with the clinical phenotypes in patients (Wojtanik 2009). The p.Arg482Gln variant is listed as pathogenic in ClinVar (Variation ID: 14486), and observed once in the Exome Variant Server (1/13006 alleles) and Genome Aggregation Database (1/246132 alleles). Based on the above information, the variant is classified as pathogenic. References: Cao H et al. Nuclear lamin A/C R482Q mutation in canadian kindreds with Dunnigan-type familial partial lipodystrophy. Hum Mol Genet. 2000; 9(1):109-12. Gambineri A et al. Monogenic polycystic ovary syndrome due to a mutation in the lamin A/C gene is sensitive to thiazolidinediones but not to metformin. Eur J Endocrinol. 2008; 159(3):347-53. Hegele R et al. Association between nuclear lamin A/C R482Q mutation and partial lipodystrophy with hyperinsulinemia, dyslipidemia, hypertension, and diabetes. Genome Res. 2000; 10(5):652-8. Hegele R et al. Heterogeneity of nuclear lamin A mutations in Dunnigan-type familial partial lipodystrophy. J Clin Endocrinol Metab. 2000b; 85(9):3431-5. Imachi H et al. A case of Dunnigan-type familial partial lipodystrophy (FPLD) due to lamin A/C (LMNA) mutations complicated by end-stage renal disease. Endocrine. 2009; 35(1):18-21. Ludtke A et al. Hepatic steatosis in Dunnigan-type familial partial lipodystrophy. Am J Gastroenterol. 2005; 100(10):2218-24. Shackleton S et al. LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nat Genet. 2000; 24(2):153-6. Speckman R et al. Mutational and haplotype analyses of families with familial partial lipodystrophy (Dunnigan variety) reveal recurrent missense mutations in the globular C-terminal domain of lamin A/C. Am J Hum Genet. 2000; 66(4):1192-8. Vigouroux C et al. Lamin A/C gene: sex-determined expression of mutations in Dunnigan-type familial partial lipodystrophy and absence of coding mutations in congenital and acquired generalized lipoatrophy. Diabetes. 2000; 49(11):1958-62. Wojtanik K et al. The role of LMNA in adipose: a novel mouse model of lipodystrophy based on the Dunnigan-type familial partial lipodystrophy mutation. J Lipid Res. 2009; 50(6):1068-79. Zwerger M et al. Myopathic lamin mutations impair nuclear stability in cells and tissue and disrupt nucleo-cytoskeletal coupling. Hum Mol Genet. 2013; 22(12):2335-49. - |
| not provided, no classification provided | literature only | Epithelial Biology; Institute of Medical Biology, Singapore | - | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | May 06, 2022 | Observed in apparent homozygous state in one individual with generalized lipodystrophy and Emery-Dreifuss muscular dystrophy in published literature (Wiltshire et al., 2013); In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function; Transgenic mice harboring this variant develop a syndrome that resembles many of the features of human familial partial lipodystrophy (Wojtanik et al., 2009); Reported as pathogenic by several other clinical laboratories in ClinVar (ClinVar Variant ID# 14486; ClinVar); Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 30275911, 16181372, 10999845, 22700598, 26662654, 28641778, 17893350, 29578370, 19859838, 25637381, 23427149, 10999791, 20130076, 11792809, 19201734, 23313286, 20625965, 24375749, 19418082, 10587585, 12647844, 28679633, 25741868, 18728124, 10739751, 19011997, 12524233, 28663758, 30165155, 31194872, 28199729, 27485410, 28450900, 11136544, 11078466, 10655060, 10810087, 31836692, 31447099, 33502018, 32041611, 16415042, 10939567) - |
| Pathogenic, criteria provided, single submitter | clinical testing | AiLife Diagnostics, AiLife Diagnostics | Dec 30, 2021 | - - |
Emery-Dreifuss muscular dystrophy 3, autosomal recessive Pathogenic:1
| Pathogenic, no assertion criteria provided | literature only | OMIM | Mar 01, 2013 | - - |
Laminopathy Pathogenic:1
| Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Apr 05, 2019 | The p.Arg482Gln variant in LMNA has been reported in at least 20 individuals with Dunnigan-type familial partial lipodystrophy (FPLD) and segregated with disease in more than 40 affected family members from at least 8 families (Cao 2000, Hegel 2000, Speckman 2000, Vigouroux 2000, Ludtke 2005, Gambineri 2008, Mory 2012, Wiltshire 2013, Lewandowski 2015). Other clinical laboratories have reported this variant in ClinVar (Variation ID 14486). This variant has also been identified in 1/111632 European chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs11575937). Please note that for diseases with clinical variability, reduced penetrance, or recessive inheritance, pathogenic variants may be present at a low frequency in the general population. Transgenic mice with the p.Arg482Gln variant of LMNA have a phenotype consistent FPLD (Wojtanik 2009). In summary, this variant meets criteria to be classified as pathogenic for FPLD in an autosomal dominant manner based on presence in multiple affected individuals, segregation studies, low frequency in the general population and in vivo functional studies. The ACMG/AMP Criteria applied: PS4, PP1_strong, PM2, PS3_moderate (Richards 2015). - |
Hutchinson-Gilford syndrome;C0406585:Lethal tight skin contracture syndrome;C0410190:Emery-Dreifuss muscular dystrophy 2, autosomal dominant;C0796031:Dilated cardiomyopathy-hypergonadotropic hypogonadism syndrome;C1449563:Dilated cardiomyopathy 1A;C1720860:Familial partial lipodystrophy, Dunnigan type;C1854154:Charcot-Marie-Tooth disease type 2B1;C1857829:Heart-hand syndrome, Slovenian type;C2750035:Emery-Dreifuss muscular dystrophy 3, autosomal recessive;C2750785:Congenital muscular dystrophy due to LMNA mutation;C5399785:Mandibuloacral dysplasia with type A lipodystrophy Pathogenic:1
| Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 31, 2018 | - - |
Charcot-Marie-Tooth disease type 2 Pathogenic:1
| Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 05, 2024 | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 482 of the LMNA protein (p.Arg482Gln). This variant is present in population databases (rs11575937, gnomAD 0.0009%). This missense change has been observed in individuals with autosomal recessive Emery-Dreifuss muscular dystrophy (EDMD) and autosomal dominant familial lipodystrophy type 2 (FLPD2) (PMID: 10587585, 10999791, 19418082, 19859838, 20130076, 20625965, 23313286, 26662654). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 14486). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt LMNA protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects LMNA function (PMID: 19201734, 20130076). For these reasons, this variant has been classified as Pathogenic. - |
Monogenic diabetes Pathogenic:1
| Pathogenic, criteria provided, single submitter | clinical testing | Translational Genomics Laboratory, University of Maryland School of Medicine | Dec 07, 2017 | The c.1445G>A variant in codon 482 (exon 8 of the RefSeq gene) of the Lamin A/C gene, LMNA, results in the substitution of Arginine to Glutamine. Mutations in the LMNA gene have been found to cause multiple disorders, collectively known as A-type laminopathies, that have overlapping signs and symptoms (23853504, 20074070, OMIM, 16364671). A-type laminopathies include familial partial lipodystrophy type 2 (FPLD2, also called familial partial lipodystrophy, Dunnigan type), Limb-Girdle muscular dystrophy type 1B, Emery-Dreifuss muscular dystrophy (EDMD), Charcot-Marie-Tooth type 2B1 disease, Hutchinson-Gilford progeria, Heart-hand syndrome, Slovenian type, mandibuloacral dysplasia, Malouf syndrome, and familial dilated cardiomyopathy (23853504, 20074070, OMIM). To date, no clear genotype-phenotype correlations have been identified (23853504, 20074070). The c.1445G>A variant has been identified in multiple individuals over multiple generations in families with clinical diagnoses of FPLD2 (22700598, 10868844, 10999845, 10587585, 10739751, 10655060). This variant was also found in the homozygous state in an individual with FPLD2 and autosomal recessive-EDMD (23313286). A different amino acid change at codon 482, Arg482Trp, has also been shown to segregate with FPLD2 (23853504, 22700598, 10999845, 10739751, 10655060). Approximately 75% of patients with FPLD2 have a mutation at Arg482, making it a mutational hotspot for FPLD2 (16364671). Multiple lines of computational evidence (SIFT, LRT, MutationTaster, FATHMM, MetaSVM, MetalR, GERP, CADD) predict the c.1445G>A variant is probably damaging to the protein structure, function, or protein-protein interaction. Indeed, functional studies of the Arg482Gln mutant protein, as well as the Arg482Trp protein, demonstrated a failure of adipocyte cell differentiation (16415042). A transgenic mouse harboring the Arg482Gln mutation recapitulates the FPLD2 phenotype and studies confirmed a lack of adipocyte renewal (19201734). ACMG criteria = PS3, PS4, PP1-strong, PM1, PM5, PP3 - |
LMNA-related disorder Pathogenic:1
| Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Aug 07, 2024 | The LMNA c.1445G>A variant is predicted to result in the amino acid substitution p.Arg482Gln. This variant has been reported in the homozygous state in two Hutterite siblings that presented with an atypical Emery-Dreifuss muscular dystrophy and in the heterozygous state in other family members with familial partial lipodystrophy and abnormal lipid profiles (Wiltshire et al. 2013. PMID: 23313286). Of note, the authors tested for the c.1445G>A variant in 482 Dariusleut and Leherleut Hutterites in Alberta and found the overall carrier frequency to be 1.45%. In addition, this variant in the heterozygous state has been reported in several unrelated families of other ethnicities to be causative for familial partial lipodystrophy in an autosomal dominant manner (Cao and Hegele. 2000. PubMed ID: 10587585; Hegele et al. 2000. PubMed ID: 10999791; Speckman et al. 2000. PubMed ID: 10739751; Vasandani et al. 2022. PubMed ID: 36397776; http://www.LOVD.nl/LMNA). This variant has not been reported in a large population database, indicating this variant is rare. In summary, the c.1445G>A variant is pathogenic for a spectrum of laminopathies in both the heterozygous and homozygous state. - |
Dilated cardiomyopathy 1A Pathogenic:1
| Pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University of Leipzig Medical Center | Jan 12, 2022 | _x000D_ Criteria applied: PS3, PS4, PM5_STR, PM1, PM2_SUP, PP3 - |
Cardiovascular phenotype Pathogenic:1
| Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 03, 2020 | The p.R482Q pathogenic mutation (also known as c.1445G>A), located in coding exon 8 of the LMNA gene, results from a G to A substitution at nucleotide position 1445. The arginine at codon 482 is replaced by glutamine, an amino acid with highly similar properties. This mutation has been detected in many unrelated individuals with familial partial lipodystrophy (FPLD) and segregated with FPLD several families (Cao H et al. Hum Mol Genet, 2000 Jan;9:109-12; Shackleton S et al. Nat Genet, 2000 Feb;24:153-6; Gambineri A et al. Eur J Endocrinol, 2008 Sep;159:347-53; Boschmann M et al. J Clin Endocrinol Metab, 2010 Apr;95:1634-43; Lewandowski KC et al. Endokrynol Pol, 2015;66:550-4; Akinci B et al. Metabolism, 2017 07;72:109-119; Kwapich M et al. Diabetes Metab, 2019 09;45:382-389; Sekizkardes H et al. J Clin Endocrinol Metab, 2019 08;104:3068-3076). This mutation has also been detected in the homozygous state in siblings reported to have atypical autosomal recessive Emery-Dreifuss muscular dystrophy (Wiltshire KM et al. Neuromuscul Disord, 2013 Mar;23:265-8). In addition, a transgenic mouse model expressing this mutation recapitulated FPLD phenotype (Wojtanik KM et al. J Lipid Res, 2009 Jun;50:1068-79). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Cardiomyopathy Uncertain:1
| Uncertain significance, flagged submission | clinical testing | Color Diagnostics, LLC DBA Color Health | Oct 05, 2023 | This missense variant replaces arginine with glutamine at codon 482 of the lamin A/C proteins. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). This variant has been shown to cause partial lipodystrophy phenotype in a transgenic mouse model (PMID: 19201734). This variant has been reported in many individuals affected with familial partial lipodystrophy (PMID: 10587585, 10999791, 19418082, 19859838, 20130076, 20625965, 26662654, 30165155, 31194872, 33803652, 34340952, 34865644, 35291351, 37679847) and in individuals affected with Emery-Dreifuss muscular dystrophy (PMID: 23313286). However, this variant has not been reported in individuals affected with cardiomyopathy in the literature. This variant has been identified in 1/246132 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Based on the available evidence, this variant is classified as a Variant of Uncertain Significance for autosomal dominant cardiomyopathy, although it is known to cause familial partial lipodystrophy (ClinVar variation ID: 14486). - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
CardioboostCm
Benign
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Pathogenic
DEOGEN2
Pathogenic
.;.;D;.;.;.;.;T
Eigen
Benign
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
LIST_S2
Pathogenic
D;D;D;D;D;D;D;D
M_CAP
Uncertain
D
MetaRNN
Uncertain
T;T;T;T;T;T;T;T
MetaSVM
Uncertain
D
MutationAssessor
Benign
L;L;L;L;.;.;.;.
MutationTaster
Benign
D;D;D;D;D;D;D;D;D
PrimateAI
Benign
T
PROVEAN
Benign
N;N;N;N;N;N;N;N
REVEL
Uncertain
Sift
Benign
D;D;D;D;D;D;D;D
Sift4G
Uncertain
D;D;D;D;T;T;T;D
Polyphen
B;B;B;.;.;B;.;.
Vest4
MVP
MPC
0.41
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at